Shares of Exact Sciences Corp. rose 6.8% Wednesday after the Madison
maker of molecular diagnostic tests said an advisory panel voted to
maintain Medicare’s current reimbursement price for the company’s
non-invasive colon cancer screening test.
Read the full Journal Sentinel article here.